Bmn 351

Phase 2

BioMarin Pharmaceutical

Bmn 351 is one of 28 therapeutic programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Duchenne Muscular DystrophyActive, not recruiting

Duchenne Muscular Dystrophy (DMD)Enrolling by invitation

Duchenne Muscular DystrophyPreclinical

Active, not recruiting

Duchenne Muscular Dystrophy (DMD)Phase 2

Enrolling by invitation

Competition

Competitive Landscape

40 competitors in Duchenne Muscular Dystrophy

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Rapamune

PPrism Pharmaceuticals

Approved

1 4

Coreg

Akero Therapeutics

Approved

1 5

Garamycin

Advil

Rifadin

1 8

Duvyzat

Italfarmaco

Phase 3

2 9

Vyondys 53

Sarepta Therapeutics

Approved

2 10

Agamree

CCatalyst Pharmaceuticals, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Duchenne Muscular Dystrophy

NCT06280209

Clinical

Trials by Indication[1]

Duchenne Muscular Dystrophy (DMD)1 trial

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Enrolling by invitation· BioMarin Pharmaceutical logo

BioMarin Pharmaceutical·Phase 2·NCT07573631·18 enrolled

Duchenne Muscular Dystrophy1 trial

A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants With Duchenne Muscular Dystrophy

Active, not recruiting· BioMarin Pharmaceutical logo

BioMarin Pharmaceutical·Preclinical·NCT06280209·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bmn 351. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bmn 351. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — BioMarin Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BioMarin Pharmaceutical

Bmn 351

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Duchenne Muscular Dystrophy (DMD)1 trial

Duchenne Muscular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News